The research will be based on the work of John Rossi, chair of the division of molecular biology at Beckman.
"The experimental treatment we are planning will give patients their own blood stem cells that have been genetically modified using ddRNAi to generate HIV resistance," Rossi said in a statement. "If this engraftment of HIV-resistant stem cells is successful, the new blood cells would be a barrier to continued HIV replication."
Benitec said it expects the therapeutic to enter the clinic in 2005, and that this will be the subject of a further agreement with City of